Roche's Q3 sales beat consensus, but guidance holds and top sellers face erosion
- Group sales rose 7% to CHF 16.1B, ahead of consensus; one analyst called the beat cosmetic, helped by a new planning system. 2026 guidance was reaffirmed, not raised.
- Xolair came in below estimates and a copycat launched in the US this month; Ocrevus, Tecentriq and Hemlibra face generics from 2030.
- Roche flagged giredestrant (FDA decision by Dec. 18) and obesity as growth hopes and has signed six China licensing deals in two months.
💡 Points
Four of Roche's five top sellers are heading toward generic or biosimilar competition, which explains the dealmaking pace: eleven China licenses since early 2025 is a bet on buying replacement growth cheaply. Giredestrant enters a crowded endocrine-therapy field and obesity is a late start, so the 2027 growth story depends on execution rather than any single product.